FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

198 stories mentioning Eli Lilly and CompanyUpdated 2d ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

What are analysts saying about Eli Lilly and Company?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on Eli Lilly and Company?

Sectors

Sector Update: Healthcare Stocks Advance Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) gained 1%.In corporate news, Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares were down 0.6%, and Lilly was rising 1.2%.Danaher (DHR) raised its full-year profit guidance on Tuesday as its fiscal Q2 results came in stronger than expected, but the company lowered the top end of its 2026 revenue growth outlook. Its shares fell past 12%.Okyo Pharma (OKYO) shares jumped past 8% after it said Chairman Gabriele Cerrone has increased his stake in the company to 10.9 million shares, or 20.5% of the company's issued share capital, with the purchase of 25,000 ordinary shares at $1.40 per share.

$DHR$LLY$NVO$OKYO
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) climbed up 1%.In corporate news, Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares were down 0.6%, and Lilly was rising 1.1%.

$LLY$NVO
Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns
US Markets

Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns

Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish pharmaceutical giant's products.The lawsuit, filed in the US District Court for the District of New Jersey, accused Lilly of being in "multiple violations of federal and state false advertising and unfair competition laws," Novo said in a statement.Lilly's ad campaigns in the US for its weight-loss drug Zepbound and Mounjaro diabetes treatment are based on what Novo described as "outdated studies" comparing highest doses of Lilly's drugs versus lower doses of Novo's Wegovy and Ozempic brands."These high-profile US advertising campaigns create the misleading impression that Lilly's medicines are superior, including by withholding critical scientific evidence about newer, more effective (US Food and Drug Administration-approved) options," Novo said.The Danish drugmaker is seeking a permanent injunction to stop the advertising across all platforms and require Lilly to run corrective ads."We have also communicated to Lilly that if they do not voluntarily pull these ads, Novo Nordisk intends to file a formal motion with the court in the coming days seeking a preliminary injunction to immediately block them, with evidence that consumers are being confused and misled by Lilly's ads," Novo said.Lilly disputed the allegations and said it intends to fight the lawsuit."The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial -- like SURMOUNT-5, which remains the only head-to-head, randomized clinical trial directly comparing tirzepatide and semaglutide in weight management," a Lilly spokesperson said in a statement e-mailed to."Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," the spokesperson said. "We stand firmly behind our advertising."Lilly shares were up 1.4% in Tuesday afternoon trade, while Novo's New York Stock Exchange-traded American depositary receipts were down 0.4%.Price: $49.41, Change: $-0.20, Percent Change: -0.40%

$LLY$NVO
Wire

Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.)Novo Nordisk (NVO) said Tuesday it filed a lawsuit against Eli Lilly (LLY) in US District Court for the District of New Jersey, alleging the drugmaker's advertising for Zepbound and Mounjaro violates federal and state false advertising and unfair competition laws.Novo Nordisk said Lilly's ads compare Zepbound and Mounjaro with lower doses of Wegovy and Ozempic while omitting information about higher-dose versions of the semaglutide drugs, making the ads misleading.The company said it is seeking a permanent injunction to stop the advertising and require Lilly to run corrective ads.Novo Nordisk added it plans to seek a preliminary injunction after Lilly declined to remove or revise the campaigns following a cease-and-desist request.An Eli Lilly spokesperson toldin an emailed response that rather than competing on the merits of its products, Novo is urging the court to stop it from communicating trial results, and it will defend against the lawsuit vigorously."We stand firmly behind our advertising. It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available - exactly what patients deserve," the spokesperson added.Price: $49.38, Change: $-0.23, Percent Change: -0.46%

$LLY$NVO
Wire

Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on some strong corporate earnings reports.In company news, 3M (MMM) reported Q2 adjusted earnings Tuesday of $2.40 per share, up from $2.16 a year earlier and above the FactSet consensus analyst estimate of $2.25. Second-quarter revenue was $6.5 billion, up from $6.34 billion a year ago and above the FactSet consensus of $6.40 billion. For fiscal 2026, the company expects adjusted EPS of $$8.80 to $8.95, up from its previous outlook of $8.50 to $8.70 and above the FactSet consensus of $8.74. 3M shares were up 8.7% around midday.Novo Nordisk (NVO) said Tuesday it filed a lawsuit against Eli Lilly (LLY) in the US District Court for the District of New Jersey alleging the drugmaker's advertising for Zepbound and Mounjaro violates federal and state false advertising and unfair competition laws. Novo shares were down 0.3%, while Lilly shares were up 1.3%.Utz Brands (UTZ) has entered into a definitive agreement through which Intersnack Group will acquire all of its outstanding common stock for $14.25 per share in cash and take it private, the companies said Tuesday. The price represents an enterprise value of about $2.9 billion and a 91% premium over Utz's closing price on July 20, the companies said. The deal is expected to close in Q4, subject to regulatory and other conditions, they said. Utz shares were up 89.5%.Danaher (DHR) reported Q2 adjusted net earnings Tuesday of $1.94 per diluted share, up from $1.80 a year earlier and above the FactSet consensus of $1.84. Second-quarter sales were $6.27 billion, up from $5.94 billion a year ago and above the FactSet consensus of $6.11 billion. For full-year 2026, the company raised its adjusted diluted EPS guidance to $8.45 to $8.60 from $8.35 to $8.55. Analysts polled by FactSet expect $8.45. Danaher shares were down $14.1%.General Motors (GM) reported Q2 adjusted diluted EPS Tuesday of $3.57, up from $2.53 a year earlier and above the FactSet consensus of $3.19. Second-quarter revenue was $48.03 billion, up from $47.12 billion a year ago and above the FactSet consensus of $47.01 billion. For 2026, the company expects adjusted EPS of $12 to $14, compared with the FactSet consensus of $12.97. GM shares were up 4.0%.MSCI (MSCI) reported Q2 adjusted EPS of $4.94, up from $4.17 a year earlier but below the FactSet consensus of $4.99. Second-quarter operating revenue was $867 million, up from $772.7 million a year ago but below the FactSet consensus of $870.7 million. MSCI shares were down 8.7%.Price: $49.45, Change: $-0.16, Percent Change: -0.33%

$DHR$GM$LLY$MMM$MSCI$NVO$UTZ
Sectors

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) fell 1.1%.In corporate news, Eli Lilly (LLY) has indicated an interest in buying shares at Scribe Therapeutics' initial public offering sufficient to raise its stake to as much as 10.9% following the offering and a concurrent private placement, Scribe said in a regulatory filing on Monday. Lilly shares were falling 2.2%.Tempus AI (TEM) agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $1.5 billion. Tempus AI shares fell 7.3%, and Personalis dropped 14%.Nuvation Bio (NUVB) shares jumped past 8% after it said Monday that follow-up data from a phase 2 trial of safusidenib in people with chemotherapy and radiotherapy-naive grade 2 IDH1-mutant glioma showed "durable" efficacy, with objective response rate of 51.9% and 36-month progression-free survival rate of 79.1%.Bristol-Myers Squibb (BMY) said Monday that it is expanding its partnership with Nvidia (NVDA) to build an AI factory dedicated to pharmaceutical research and development. Bristol-Myers Squibb shares were shedding 0.9%.

$BMY$LLY$NUVB$PSNL$TEM
Sectors

Sector Update: Healthcare Stocks Softer Monday Afternoon

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index shedding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.6%.The iShares Biotechnology ETF (IBB) fell 0.7%.In corporate news, Eli Lilly (LLY) has indicated an interest in buying shares at Scribe Therapeutics' initial public offering sufficient to raise its stake to as much as 10.9% following the offering and a concurrent private placement, Scribe said in a regulatory filing on Monday. Lilly shares were falling 1.4%.Tempus AI (TEM) agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $1.5 billion. Tempus AI shares fell 6.9%, and Personalis dropped 11%.Bristol-Myers Squibb (BMY) said Monday that it is expanding its partnership with Nvidia (NVDA) to build an AI factory dedicated to pharmaceutical research and development. Bristol-Myers Squibb shares were down 0.4%.

$BMY$LLY$PSNL$TEM
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said in a note. Lilly shares were up 0.7%.Intuitive Surgical (ISRG) shares fell nearly 14%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.1% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Xencor (XNCR) shares jumped about 13% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$GSK$ISRG$LLY$XNCR
Wire

Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said.The firm said in a Thursday note that generic semaglutide is expected to supply only about 25% to 30% of the global branded GLP-1 market by 2030, citing bottlenecks in fill-finish capacity, device integration and auto-injector pen manufacturing rather than active pharmaceutical ingredient production.Research into Indian suppliers and the broader device supply chain suggests generic manufacturers will struggle to scale production despite multiple market entrants, leaving a structural supply shortfall, according to the report.UBS estimates the global GLP-1 market will reach 40 million to 50 million patients by 2030, while generic manufacturers will have the capacity to serve only about 10 million to 15 million patients. The remaining 70% to 75% of the market is likely to remain branded, supporting durable market share for Eli Lilly's portfolio.The investment firm expects Eli Lilly to outperform consensus earnings estimates over the long term, supported by higher-efficacy therapies such as Zepbound and its next-generation pipeline, including retatrutide and amylin combinations, which the firm believes will help sustain premium pricing and market leadership despite generic competition.UBS has a buy rating on Eli Lilly with a price target of $1,425.Price: $1183.42, Change: $+14.25, Percent Change: +1.22%

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Merck (MRK) shares gained 3% after it said Thursday that the Food and Drug Administration has approved Lipfendra 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.UnitedHealth (UNH) shares rose 1.7% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 32% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 0.8%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped past 10%.

$ABT$ATAI$LLY$MRK$UNH
Wire

Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says

Eli Lilly (LLY) could see further momentum from positive amylin and tirzepatide data supporting its GLP-1 pipeline momentum, UBS said in a note Wednesday.The note said phase 1b data showed the combination delivered 25.5% weight loss at 24 weeks, and 29% weight loss at 32 weeks in a small patient group, following prior eloralintide monotherapy data showing 20% weight loss. Eloralintide is a selective amylin receptor agonist in development."This is a good read-through to the upcoming Phase II data which we think will be presented at obesity week this year (Nov 14-17) and the title will be released in October," the report said.If phase 2 data confirms 25% to 30% weight loss, eloralintide could become the second obesity drug after retatrutide to reach that level of efficacy, while potentially offering better tolerability than retatrutide and tirzepatide, the report added."This coincides with our thesis that LLY's incretin portfolio taken together offers many options for patients," the note said.UBS has a buy rating and a $1,425 price target.Price: $1176.53, Change: $+19.90, Percent Change: +1.72%

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.4%.In corporate news, UnitedHealth (UNH) shares rose 3.3% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 33% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 1.3%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped 11%.

$ABT$ATAI$LLY$UNH
Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline
US Markets

Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline

AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion.The purchase price comprises $2.8 billion in upfront cash and about $1 billion in contingent value rights, the pharmaceutical giant said Thursday.New York-based AtaiBeckley is developing rapid-acting therapies for mental health conditions, with its BPL-003 lead program currently in phase 3 development as an intranasal therapy for treatment-resistant depression.Under the agreement, Eli Lilly will pay $6.75 per share in cash upon closing and up to $2.50 per share in CVRs.The CVR payment includes $1 upon starting a phase 3 trial for VLS-01, a dissolving oral film targeting treatment-resistant depression, within four years of closing and another $1 upon US regulatory approval and Drug Enforcement Administration rescheduling of the drug within seven years. The remaining $0.50 is tied to US regulatory clearance and rescheduling of BPL-003, within five years."Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, president of Lilly Neuroscience, said in a statement. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."Earlier this year, Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, Kelonia Therapeutics for up to $7 billion, Orna Therapeutics for up to $2.4 billion, and three vaccine developers, Curevo, Vaccine Company, and LimmaTech Biologics for up to $1.5 billion, $1.55 billion, and $780 million, respectively.In April, the drugmaker raised its full-year outlook and reported better-than-expected first-quarter results. The company's second-quarter results are scheduled for Aug. 5.AtaiBeckley shares rose 33% in recent Thursday trading, while Eli Lilly was up 1.4%.Price: $7.16, Change: $+1.80, Percent Change: +33.49%

$ATAI$LLY
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Thursday

Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) up 0.5%.UnitedHealth Group (UNH) stock was up more than 7% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS outlook.Abbott Laboratories (ABT) shares were up more than 5% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS guidance.Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $2.8 billion in cash plus potential milestone payments of up to $1.0 billion, the companies said. AtaiBeckley stock was up more than 33% pre-bell.

$ABT$ATAI$IBB$LLY$UNH$XLV
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Novo Nordisk (NVO) shares gained 2.9% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 9%.Veradermics (MANE) shares jumped 12% after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares were fractionally higher.

$ELV$LLY$MANE$NVO
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.3%.In corporate news, Novo Nordisk (NVO) shares rose 2.5% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 8%.Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected Q2 results, driven by growth in its innovative medicine and medical device businesses. Its shares were still down 1.7%.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares shed 0.4%.

$ELV$JNJ$LLY$NVO
Wire

Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Administration for its drug selpercatinib, Retevmo, to treat adult and pediatric patients two years and older with locally advanced or metastatic solid tumors carrying a RET gene fusion, a genetic alteration that can drive tumor growth.The approval applies to patients who have progressed on prior treatment or have no satisfactory alternative options, as detected by an FDA-approved test.The drug previously held accelerated approval for this indication, the notice said.In a trial of 75 patients with RET fusion-positive tumors outside of lung and thyroid cancer, the drug showed a 47% overall response rate, or share of patients whose tumors shrank significantly, with a median response duration of 24.5 months.The FDA approved the application two months ahead of schedule, and the drug holds orphan drug designation for this tissue-agnostic indication, meaning it applies regardless of where the tumor originated.Price: $1155.18, Change: $-26.69, Percent Change: -2.26%

$LLY
Wire

UBS Adjusts Eli Lilly Price Target to $1,425 From $1,250, Maintains Buy Rating

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,296.46, according to analysts polled by FactSet.Price: $1191.61, Change: $+3.03, Percent Change: +0.25%

$LLY
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

BofA Securities Adjusts Eli Lilly Price Target to $1,334 From $1,251

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,283.12, according to analysts polled by FactSet.Price: $1189.74, Change: $-27.22, Percent Change: -2.24%

$LLY

Showing 61-80 of 198

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company